Ocugen (OCGN) Proxy filing summary

Executive summary

• Special meeting scheduled for September 21, 2026, to vote on increasing authorized shares.

• Proposal aims to support ongoing clinical progress, commercial readiness, and long-term growth.

• Forward-looking statements highlight anticipated benefits and future strategies, subject to risks and uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on a proposal to increase the number of authorized shares.

• Voting is open until September 20, 2026, with instructions provided for proxy voting.

Board of directors and corporate governance

• Directors and executive officers are participating in the proxy solicitation and may have direct or indirect interests.

• Information on directors’ and officers’ security holdings is disclosed in the proxy statement and annual meeting materials.